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Abstract
Objective: The	diagnosis	of	childhood‐onset	cerebellar	ataxia	(CA)	is	often	challenging	
due to variations in symptoms and etiologies. Despite the known regional differences 
in	the	prevalence	of	etiologies	underlying	CA,	the	frequency	and	characteristics	of	
CA	in	Japan	remain	unclear.	We	conducted	a	questionnaire‐based	survey	to	identify	
the	clinical	characteristics	of	childhood‐onset	CA	in	the	Japanese	population.
Materials and Methods: Questionnaires	were	sent	to	1,103	board‐certified	pediatric	
neurologists	 in	Japan	from	2016	to	2017.	The	primary	survey	requested	the	num‐
ber	of	patients	with	CA	under	care,	and	the	follow‐up	secondary	questionnaire	re‐
quested	additional	clinical	characteristics	of	the	patients.
Results: The	primary	survey	obtained	578	responses	(response	rate,	52.4%)	on	385	
patients	with	CA,	 including	171	diagnosed	and	214	undiagnosed	cases	 (diagnostic	
rate,	 44.4%).	 The	most	 frequent	 etiology	 was	 dentatorubropallidoluysian	 atrophy	
(DRPLA),	followed	by	mitochondrial	disorders	and	encephalitis.	The	secondary	sur‐
vey obtained the clinical characteristics of 252 cases (119 diagnosed and 133 undi‐
agnosed	cases).	Multiple	logistic	regression	analysis	revealed	that	a	younger	age	at	
onset,	hearing	issues,	and	short	stature	were	associated	with	a	higher	risk	of	remain‐
ing	undiagnosed	with	CA	in	Japan.
Conclusions: The	diagnostic	 rate	 of	 childhood‐onset	CA	 in	 the	 current	 study	was	
comparable to those reported in other countries. The high prevalence of autosomal 
dominant	ataxia,	especially	DRPLA,	was	a	signature	of	CA	in	Japan.	These	data	offer	
insights	into	the	characteristics	of	childhood‐onset	CA	in	the	Japanese	population.
K E Y W O R D S
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1  | INTRODUC TION
The prevalence rates and etiologies of childhood‐onset cerebellar 
ataxia	(CA),	which	defines	a	heterogeneous	group	of	disorders,	vary	
across	regions	(Musselman	et	al.,	2014).	For	example,	studies	have	
shown	 that	 dentatorubropallidoluysian	 atrophy	 (DRPLA)	 is	 more	
frequent	 in	Asia	and	Portugal	compared	to	the	rest	of	Europe	and	
the	Mediterranean	(Coutinho	et	al.,	2013;	van	de	Warrenburg	et	al.,	
2014).
The	 information	 of	 childhood‐onset	 CA	 in	 Japan	 is	 limited.	 A	
study	including	both	adult‐	and	childhood‐onset	SCAs	in	Japan	re‐
ported that sporadic cases accounted for approximately double the 
number	of	hereditary	cases	and	that,	among	hereditary	SCAs,	 the	
autosomal	dominant	(AD)	type	was	more	common	than	the	autoso‐
mal	recessive	(AR)	type;	this	finding	is	contrast	to	that	observed	in	
the	Caucasian	population,	in	which	Machado–Joseph	disease/SCA3,	
SCA6,	 and	 DRPLA	 are	 the	 most	 common	 types	 (Tsuji,	 Onodera,	
Goto,	&	Nishizawa,	2008).	Furthermore,	Friedreich	ataxia	with	GAA	
repeat	expansion,	the	most	common	form	of	hereditary	SCAs	among	
Caucasians,	 has	 never	 been	 reported	 in	 the	 Japanese	 population	
(Maruyama	 et	 al.,	 2002).	 However,	 no	 studies	 thus	 far	 addressed	
childhood‐onset	CA	in	Japan.
Due to the diverse symptoms and pathogenesis along with vari‐
ations	in	etiologies	across	regions,	the	diagnosis	of	childhood‐onset	
CA	is	often	challenging	and	might	be	facilitated	by	a	better	under‐
standing	of	 the	prevalence	of	 underlying	 etiologies.	 Thus,	 surveil‐
lance is necessary to update the epidemiology of childhood‐onset 
CA.
In	the	current	study,	we	conducted	a	survey	to	collect	informa‐
tion	on	childhood‐onset	CA	 in	Japan	by	sending	questionnaires	to	
pediatric neurologists. We also compared the clinical features be‐
tween	patients	with	and	without	CA	diagnosis	to	further	delineate	
the	clinical	presentation	of	childhood‐onset	CA.
2  | MATERIAL S AND METHODS
This	 cross‐sectional	 questionnaire‐based	 survey	 was	 approved	
by the ethics committee of the National Center of Neurology and 
Psychiatry	 in	 Tokyo,	 Japan	 (approval	 number	 A2016‐070).	 The	
primary objective was to determine the number of patients with 
childhood‐onset	CA	 in	Japan	and	the	prevalence	rates	of	underly‐
ing etiologies. The secondary objective was to elucidate the clinical 
characteristics	of	childhood‐onset	CA.
Questionnaires	 were	 sent	 via	 postal	 mail	 to	 1,103	 pediatric	
neurologists who were certified by The Japanese Society of Child 
Neurology	as	the	majority	of	the	patients	with	childhood‐onset	CA	
in Japan were presumed to be under the care of these specialists. 
Furthermore,	 assessment	 of	 the	 neurological	 findings	 including	
ataxia by the pediatric neurologists was considered to be reliable.
The	questionnaires	were	 sent	 in	 two	phases.	The	primary	 sur‐
vey	 requested	 the	number	and	diagnosis	of	patients	with	CA	as	a	
symptom who were under the care of the pediatric neurologist. 
Information	 on	 patients	with	 CA	who	 did	 not	 receive	 a	 definitive	
diagnosis	 was	 also	 requested.	 The	 secondary	 survey	 requested	
further	clinical	information	of	the	patients,	including	disease	onset,	
sex,	 family	history,	and	clinical	course	 (progressive	or	nonprogres‐
sive),	but	did	not	include	personal	information	that	could	specify	the	
individual.
The	primary	survey	took	place	from	November	2016	to	February	
2017. The secondary survey was sent to those physicians who agreed 
to participate in the secondary survey among those who initially re‐
sponded	to	have	at	 least	one	patient	with	CA	under	care.	All	data	
were	anonymized	by	the	responding	physicians,	and	the	answers	to	
the	questionnaires	were	sent	back	by	postal	mail.
The inclusion criteria were as follows: disease onset between 
birth	and	18	years	of	age,	presence	of	cerebellar	atrophy	or	hypo‐
plasia	 confirmed	by	magnetic	 resonance	 imaging,	 and	presence	of	
ataxia.
The	 data	 extracted	 from	 the	 questionnaires	 were	 transcribed	
into an excel chart and categorized into two groups: one group com‐
prising	patients	without	a	definitive	diagnosis	 (undiagnosed	group)	
and one group comprising patients with a diagnosis of a specific dis‐
order	(diagnosed	group).	The	number	of	patients	with	specific	diag‐
noses was determined in the diagnosed group.
In	addition,	multiple	 logistic	regression	analysis	was	performed	
to	 assess	 the	 ability	 of	 independent	 variables	 among	 symptoms,	
signs,	and	disease	course	 to	predict	 the	definitive	diagnosis	of	CA	
in	the	standard	medical	setting	of	Japan.	A	stepwise	approach	was	
adopted for variable selection with inclusion and exclusion of criteria 
with a p	value	of	.15.	The	C‐statistic	and	the	Hosmer–Lemeshow	test	
were used to measure the goodness of fit for the logistic regression 
model.	A	p value of <.05 was considered as statistically significant 
in	all	analyses.	Statistical	analysis	was	performed	with	SAS	ver.	9.4	
(SAS	Institute).
3  | RESULTS
Figure	 1	 describes	 the	 flowchart	 for	 data	 collection	 via	 the	 pri‐
mary	and	secondary	surveys.	A	total	of	578	replies	were	obtained	
from	1,103	requests	sent	during	the	primary	survey	(response	rate	
52.4%).	Of	the	578	physicians	who	replied,	150	stated	that	they	had	
patients	with	childhood‐onset	CA	under	care,	which	yielded	 infor‐
mation	 on	 a	 total	 of	 385	 cases.	 Therefore,	 it	was	 speculated	 that	
between	150/1,103	 (13.6%)	 and	150/578	 (26.0%)	 of	 the	pediatric	
neurologists in Japan were engaged in the treatment of childhood‐
onset	CA.	The	cases	collected	via	the	primary	survey	included	171	
and	214	patients	with	and	without	diagnosis,	respectively,	indicating	
a	diagnostic	rate	of	44.4%	for	childhood‐onset	CA.
The	 collected	 responses	 covered	 all	 of	 the	 47	 prefectures	 in	
Japan,	with	at	least	one	patient	reported	in	39	prefectures	and	zero	
patients	reported	in	eight	prefectures	(Fukushima,	Fukui,	Hiroshima,	
Tokushima,	Wakayama,	Kochi,	 Ehime,	 and	Oita;	 Figure	2).	 The	 re‐
sponses	were	obtained	from	university	hospitals,	general	hospitals,	
special	functioning	hospitals	(neurology,	pediatrics,	or	rehabilitation),	
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regional	medical	care	support	hospitals,	clinics,	healthcare	centers,	
and	others	(included	research	institutes	and	unanswered).	The	ma‐
jority of the reported patients were under care of one of the fol‐
lowing:	university	hospital,	 general	hospital,	or	 special	 functioning	
hospital	(Figure	3).
In the secondary survey sent to the 150 pediatric neurolo‐
gists,	 detailed	 clinical	 information	 on	 263	 patients,	 including	 125	
diagnosed	 and	 138	 undiagnosed	 patients,	 was	 obtained	 from	 113	
physicians	 responding	 to	 the	 survey	 (response	 rate,	 75.3%).	 After	
examination	by	the	authors,	11	patients,	including	six	diagnosed	and	
five	undiagnosed	patients,	were	excluded	because	they	did	not	fulfill	
the	inclusion	criteria	of	the	current	study.	Therefore,	information	on	
252	patients,	including	119	diagnosed	and	133	undiagnosed	patients,	
was included in the final analysis. The patients' current age ranged 
from	1	to	55,	and	there	were	201	individuals	who	were	under	age	20.
Table 1 summarizes the diagnoses of the patients with childhood‐
onset	CA	 identified	 via	 the	 primary	 survey.	Of	 the	 171	 diagnosed	
cases	obtained	by	the	primary	survey,	the	most	frequent	diagnosis	
was	DRPLA	(n	=	30),	followed	by	mitochondrial	disorders	(n	=	20),	en‐
cephalitis (n	=	16),	Joubert	syndrome	and	related	disorders	(n	=	14),	
and	ataxia	telangiectasia	(AT)	and	related	disorders	(n	=	14).
There	 were	 61	 patients	 with	 spinocerebellar	 ataxias	 (SCAs).	
Among	these,	the	AD	SCAs	(n	=	37)	were	more	predominant	than	the	
AR	SCAs	(n	=	21).	The	most	frequent	AD	SCA	was	DRPLA	(n	=	30),	
followed	 by	 SCA29	 (n	 =	 4).	 Among	 the	 AR	 SCAs,	 AT	 and	 related	
disorder (n	=	14)	were	 the	most	 common,	 followed	by	ataxia	with	
oculomotor	apraxia	 type	1	 (AOA1;	n	=	5).	Other	AR	SCAs	such	as	
Marinesco–Sjögren	 syndrome	 and	 infantile‐onset	 spinocerebellar	
degeneration,	albeit	observed,	were	less	common.
Among	 the	mitochondrial	 diseases,	 there	were	 Leigh	 enceph‐
alopathy (n	 =	 5);	 myoclonus	 epilepsy	 associated	 with	 ragged‐red	
fibers (n	=	3);	pyruvate	dehydrogenase	complex	deficiency	(n	=	3);	
mitochondrial	 myopathy,	 encephalopathy,	 lactic	 acidosis,	 and	
stroke‐like episodes (n	=	2);	chronic	progressive	external	ophthal‐
moplegia (n	=	1);	neuropathy,	ataxia,	and	retinitis	pigmentosa	(n	=	1);	
and other nonspecified mitochondrial disorders (n	=	5);	respectively.
The	 secondary	 survey	 provided	 more	 detailed	 information,	
and	 119	 diagnosed	 patients	 (Table	 A1	 in	 Appendix	 1)	 identified	
via the secondary survey were analyzed to elucidate age of onset 
F I G U R E  1  The	flowchart	of	data	collected	via	the	primary	and	secondary	survey.	Questionnaires	were	sent	to	1,103	board‐certified	
pediatric	neurologists	in	Japan.	The	response	rates	were	52.3%	in	the	primary	survey	and	75.3%	in	the	secondary	survey.	A	total	of	385	
cases,	including	171	diagnosed	and	214	undiagnosed	cases,	with	cerebellar	ataxia	were	reported,	with	a	diagnostic	rate	of	44.4%
F I G U R E  2   The prefectures of Japan which the responses were 
obtained. Black indicates at least one patient was present in the 
prefecture,	and	gray	indicates	responses	were	obtained,	but	0	
patient	present.	Gray	prefectures	are	Fukushima,	Fukui,	Hiroshima,	
Tokushima,	Wakayama,	Kochi,	Ehime,	and	Oita,	from	north	to	south
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for	 childhood‐onset	CA	 in	 Japan	 (Table	2).	Briefly,	 among	 the	119	
patients,	 the	 ages	 of	 disease	 onset	were	 <1	 year	 (infantile‐onset),	
1–5	years	 (early	 childhood‐onset),	 and	>6	years	 (middle	 childhood	
to	adolescence	onset)	in	56	(48.3%),	34	(29.3%),	and	26	(22.4%)	pa‐
tients,	respectively,	whereas	information	on	age	at	onset	was	miss‐
ing	in	three	patients.	In	the	infantile‐onset	group,	the	most	common	
underlying disease was Joubert syndrome and related disorders 
(n	=	11),	followed	by	SCA29	(n	=	4),	mitochondrial	diseases	(n	=	4),	
and CASK‐related disorders (n	 =	 4).	 In	 the	 early	 childhood‐onset	
group,	the	most	common	etiology	was	DRPLA	(n	=	8),	followed	by	
AT	(n	=	7),	and	mitochondrial	diseases	(n	=	7).	In	the	middle	childhood	
to	adolescent‐onset	group,	the	most	common	diagnosis	was	DRPLA	
as well (n	=	8),	followed	by	encephalitis	(n	=	5).	Of	note,	among	the	
patients	 with	 the	 frequently	 observed	 hereditary	 diseases,	 the	
mean	ages	at	onset	were	6.4	(±5.0),	0.2	(±0.20),	2.5	(±1.6),	and	3.9	
(±4.0)	years	for	DRPLA,	SCA29,	AT	and	related	disorder,	and	AOA1,	
respectively.
Assessment	of	the	119	cases	with	a	focus	on	family	history	re‐
vealed	that	35	patients	(30.2%)	had	a	positive	family	history,	whereas	
the	remaining	81	patients	(69.8%)	had	a	negative	family	history	in	the	
diagnosed group. No information on family history was available for 
three	patients.	Among	those	with	a	positive	family	history,	DRPLA	
(n	 =	 15)	 was	 the	 most	 common,	 whereas	 mitochondrial	 diseases	
(n	 =	11),	AT	 (n	 =	9),	 and	 Joubert	 syndrome	 (n	 =	7)	were	 the	most	
common	among	the	patients	with	a	negative	family	history	(Table	2).
Among	the	diagnosed	patients	in	the	secondary	survey	(n	=	119),	
54	patients	 (45.4%)	exhibited	a	progressive	clinical	 course,	64	pa‐
tients	(53.8%)	exhibited	a	nonprogressive	course;	there	was	one	pa‐
tient with missing information on their clinical course. Of the cases 
with	 the	 progressive	 course,	 the	 most	 frequent	 etiologies	 were	
DRPLA	(n	=	18),	AT	and	related	disorder	(n	=	9),	and	mitochondrial	
diseases (n	=	7).	In	contrast,	among	the	patients	with	a	nonprogres‐
sive	course,	the	most	common	cause	was	Joubert	syndrome	and	re‐
lated disorders (n	=	12),	followed	by	mitochondrial	diseases	(n	=	7)	
and encephalitis (n	=	5;	Table	2).
The	common	symptoms	and	signs	associated	with	CA	 in	252	
patients for whom data were obtained via the secondary survey 
were	 intellectual	 disability	 (76.2%),	 followed	 by	 motor	 develop‐
mental	 delay	 (52.8%),	 seizures	 (31.3%),	 hypotonia	 (28.6%),	 in‐
creased	deep	 tendon	 reflexes	 (26.2%),	 ophthalmologic	 problems	
(19.8%),	 muscle	 weakness	 (19.0%),	 and	 involuntary	 movements	
(18.7%).
Multiple logistic regression analysis of the 252 patients in the 
secondary	 survey,	 performed	 to	 identify	 predictive	 variables	 for	
definitive	diagnosis,	demonstrated	that	age	onset	(odds	ratio	[OR]	
1.09,	95%	confidence	 interval	 [CI]	 1.01–1.18,	p	 =	 .03),	 hearing	 is‐
sues	 (OR	0.07,	95%CI	0.01–0.88,	p	=	 .04),	short	stature	 (OR	0.32,	
95%CI	 0.12–0.82,	 p	 =	 .02),	 and	 decreased	 deep	 tendon	 reflexes	
(OR	6.38,	95%CI	2.03–20.1,	p	<	 .01)	were	significantly	associated	
with	definitive	diagnosis	for	childhood‐onset	CA	in	Japan	(Table	3).	
Albeit	not	statistically	significant,	negative	family	history	and	lack	
of motor developmental delays tended to be associated with failure 
of	 a	 definitive	 diagnosis	 (Table	 3).	 The	C‐statistics	was	 0.70,	 and	
the p	 value	of	Hosmer‐Lemeshow	 test	was	 .76,	 indicating	a	good	
model fitting.
We further examined diagnostic tests that contributed to de‐
finitive	 diagnosis	 and	 found	 that	 genetic	 analysis,	 brain	 imaging,	
and	testing	of	body	fluids	(blood	and	cerebrospinal	fluid)	were	re‐
quired	in	73.1%,	49.6%,	and	17.6%	of	the	patients	with	a	definitive	
diagnosis	 of	 childhood‐onset	 CA,	 respectively.	Of	 note,	multiple	
test modalities were necessary to confirm the diagnosis in some 
patients.
F I G U R E  3   The charts showing the types of medical facilities which the responses were obtained. The facilities with no patient included 
more	clinics,	and	lower	number	of	university	hospitals	compared	to	the	facilities	with	at	least	one	patient.	The	majority	of	the	facility	with	at	
least	one	patient	consisted	of	university	hospitals,	general	hospitals,	and	special	functioning	hospitals
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TA B L E  1   Summary of the 171 diagnosed cases collected via primary survey
Diagnosis Number of patients Disease category
Dentatorubropallidoluysian atrophy 30 SCAs
Mitochondrial disorder 20 Inborn error of metabolism
Encephalitis 16 Encephalitis
Joubert syndrome and related disorder 14 Joubert syndrome and related disorder
Ataxia	telangiectasia	and	related	disorders 14 SCAs
Dandy–Walker	variants 5 Brain malformation
Ataxia	with	oculomotor	apraxia	type	1 5 SCAs
SCA29 4 SCAs
CASK mutation 4 Other genetic disorders
KIF1A mutation 4 Other genetic disorders
Opsoclonus myoclonus syndrome 4 Paraneoplastic cerebellar degeneration
Spinocerebellar degeneration 3 SCAs
Congenital disorder of glycosylation 3 Inborn error of metabolism
CACNA1A mutation 3 Other genetic disorders
H‐ABC 3 Degenerative disorders
Cerebellar hypoplasia 2 Brain malformation
SCA5 2 SCAs
Peroxisomal biogenesis disorders 2 Inborn error of metabolism
Glut1	deficiency 2 Inborn error of metabolism
SEPSECS mutation 2 Pontocerebellar hypoplasia
Phenytoin side effect 2 Others
Cerebellar vermis deficiency 1 Brain malformation
Chiari malformation 1 Brain malformation
Holoprosencephaly 1 Brain malformation
18 trisomy 1 Chromosomal and congenital abnormality
21 trisomy 1 Chromosomal and congenital abnormality
5p syndrome 1 Chromosomal and congenital abnormality
Chromosomal abnormality 1 Chromosomal and congenital abnormality
Partial monosomy 13 1 Chromosomal and congenital abnormality
Phelan–McDermid	syndrome 1 Chromosomal and congenital abnormality
Cockayne syndrome 1 Chromosomal and congenital abnormality
Pontocerebellar hypoplasia type 7 1 Pontocerebellar hypoplasia
Marinesco–Sjögren	syndrome 1 SCAs
SCA2 1 SCAs
Infantile‐onset spinocerebellar degeneration 1 SCAs
L‐2‐hydroxyglutaric	aciduria 1 Inborn error of metabolism
Congenital	GPI	deficiency 1 Inborn error of metabolism
KMT2B mutation 1 Other genetic disorders
STXBP1 mutation 1 Other genetic disorders
PLA2G6‐associated neurodegeneration 1 Other genetic disorders
MECP2 duplication 1 Other genetic disorders
Ceroid	lipofuscinosis	neuronal	6 1 Other genetic disorders
MTHFR	deficiency 1 Other genetic disorders
4H	syndrome 1 Degenerative disorders
Infantile neuroaxonal dystrophy 1 Degenerative disorders
Chédiak‐Higashi syndrome 1 Abnormal	immune	system
Post‐head trauma 1 Others
Cerebral palsy 1 Others
Abbreviations:	4H	syndrome,	hypomyelination	with	hypogonadotropic,	hypogonadism	and	hypodontia	syndrome;	GPI,	glucose	phosphate	isomer‐
ase;	H‐ABC,	hypomyelination	with	atrophy	of	the	basal	ganglia	and	cerebellum;	MTHFR,	methylenetetrahydrofolate	reductase;	SCA,	spinocerebellar	
ataxia.
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Among	 the	 undiagnosed	 cases,	 45	 patients	 underwent	 ge‐
netic	 analyses	 including	 whole‐exome	 sequencing	 (WES;	 n	 =	 10)	
and disease‐specific genetic analysis (n	=	14).	No	precise	informa‐
tion regarding genetic analyses was available for the remaining 21 
patients.
The most common brain imaging finding that contributed to the 
diagnosis	was	molar	tooth	sign	(vermian	hypoplasia)	in	Joubert	syn‐
drome and related disorders. Other brain imaging findings which 
contributed to the diagnosis in the diagnosed group were diffuse 
brain	atrophy	in	DRPLA,	basal	ganglia	abnormalities	in	mitochondrial	
TA B L E  2   Summary of the clinical features with 119 diagnosed cases collected via secondary survey
Diagnosis N
Onset Family history Clinical course
<1 year 1−5 year ≥6 year Yes No Progressive Nonprogressive
Dentatorubropallidoluysian atrophy 20 3 8 8 15 4 18 2
Mitochondrial disorder 14 4 7 2 3 11 7 7
Joubert syndrome and related disorder 12 11 1  5 7  12
Ataxia	telangiectasia	and	related	disorders 11 3 7 1 2 9 9 2
Encephalitis 6  1 5  6 1 5
Ataxia	with	oculomotor	apraxia	type	1 5 2 1 2  5 5  
SCA29 4 4   1 3  4
CASK mutation 4 4    4  4
CACNA1A mutation 4 2 1 1  4 1 3
Glut1	deficiency 3 3   3  1 2
KIF1A mutation 3 2 1   3  3
Dandy–Walker	variants 2 2    2  2
SEPSECS mutation 2  1 1  2 1 1
Congenital disorder of glycosylation 2 2   1 1  2
Marinesco–Sjögren	syndrome 2 1  1  2 1 1
Peroxisomal biogenesis disorders 2  2  2  1 1
PLA2G6‐associated neurodegeneration 2  2  2  2  
TUBA1A mutation 1 1    1  1
Cerebellar hypoplasia 1 1    1  1
Holoprosencephaly 1 1    1   
Pontocerebellar hypoplasia type 7 1 1      1
Chromosome 22 partial duplication 1 1    1  1
Cockayne syndrome 1 1    1  1
Phelan–McDermid	syndrome 1 1    1  1
Phenytoin side effect 1   1  1  1
Opsoclonus myoclonus syndrome 1  1   1  1
SCA5 1 1    1  1
SCA13 1  1   1  1
SCA2 1    1  1  
Infantile‐onset spinocerebellar degeneration 1 1    1  1
Friedreich	ataxiaa 1   1  1 1  
Spinocerebellar degeneration 1 1    1 1  
Multiple system atrophy 1   1  1 1  
KCNA2 mutation 1 1    1 1  
LONP1 mutation 1   1  1 1  
MECP2 duplication 1 1     1  
STXBP1 mutation 1 1    1  1
Chédiak‐Higashi syndrome 1     1  1
Abbreviation:	SCA,	spinocerebellar	ataxia.
aNot confirmed by gene analysis. 
     |  7 of 9ONO et al.
diseases,	 calcification	 of	 the	 basal	 ganglia	 in	Cockayne	 syndrome,	
and	vermian	atrophy	with	enlarged	posterior	fossa	in	Dandy–Walker	
variant.	Among	 the	 tests	 for	body	 fluids,	 elevated	 lactate	 and	py‐
ruvic	 acid	 in	 mitochondrial	 diseases,	 elevated	 alpha‐fetoprotein,	
and	decreased	immunoglobulin	A	in	AT	were	described	as	contribu‐
tory to the diagnosis. Other findings such as giant granules in white 
blood cells in Chédiak‐Higashi syndrome and low blood glucose 
level	in	cerebrospinal	fluid	in	GLUT1	deficiency	were	also	reported	
as	 contributors	 to	 the	 diagnosis.	 Abnormal	 findings	 in	 transferrin	
electrophoresis were contributory to the diagnosis of carbohydrate‐
deficient glycoprotein syndrome type 1a.
4  | DISCUSSION
The current study demonstrated that definitive diagnosis was achieved 
in	44.4%	of	the	patients	with	childhood‐onset	CA	in	Japan,	with	the	
55.6%	of	the	patients	remaining	undiagnosed;	this	finding	is	in	agree‐
ment	with	previously	published	diagnostic	rate	of	47%	in	2012	from	
Canada	(Al‐Maawali,	Blaser,	&	Yoon,	2012).	Among	the	patients	with	
a	 definitive	 diagnosis,	 DRPLA,	 mitochondrial	 diseases,	 encephalitis,	
AT	and	related	disorders,	and	Joubert	syndrome	and	related	disorders	
were	the	most	common	etiologies	of	childhood‐onset	CA	in	Japan.
Given	 that	 the	 population	 of	 Japanese	 children	 younger	 than	
20	years	is	21,580,000	(e‐Stat,	2019,	January	20)	and	that	201	pa‐
tients	younger	than	20	years	were	included	in	the	current	study,	the	
estimated	overall	prevalence	of	children	with	CA	in	Japan	is	at	least	
0.93	per	100,000.	Systematic	reviews	and	meta‐analyses	to	assess	
the	 frequency	 of	 childhood‐onset	 CA	 reported	 the	 overall	 preva‐
lence	of	ataxia	in	Europe	was	no	more	than	26	per	100,000	children	
(Musselman	et	 al.,	 2014),	which	 is	higher	 than	our	 findings,	which	
might be attributable to differences in prevalence rates across coun‐
tries or differences in methods used across studies.
Studies	 suggest	 the	 significance	 of	 age	 at	 onset,	 clinical	 pro‐
gression	 (progressive	 or	 nonprogressive),	 and	 family	 history	 for	
the	 definitive	 diagnosis	 of	 childhood‐onset	 CA	 (Fogel	 &	 Perlman,	
2007;	 Singer,	 Mink,	 Gilbert,	 &	 Jankovic,	 2015).	 The	 average	 age	
at	onset	for	AT	in	the	current	study	(2.5	±	1.6	years)	 is	 lower	than	
the	 previously	 reported	 onset	 age	 of	 above	 5	 years	 (Singer	 et	 al.,	
2015).	Furthermore,	the	onset	age	for	AOA1,	which	follows	a	similar	
clinical	course	as	AT,	was	reported	as	approximately	7	years	(Fogel	
&	Perlman,	2007),	which	was	3.9	±	4.0	years	 in	 the	current	study,	
indicating	 that	 the	 onset	 of	 AT	 and	AOA1	might	 be	 earlier	 in	 the	
Japanese	population.	DRPLA	is	a	well‐known	AD	SCA	with	an	early	
childhood‐onset	(Fogel,	2012;	Singer	et	al.,	2015).	Studies	assessing	
adult‐onset	as	well	as	childhood‐onset	DRPLA	reported	the	age	of	
onset	 for	DRPLA	as	36.9	±	18.0	years	 in	 Japan	 (Al‐Maawali	et	al.,	
2012;	Maruyama	et	al.,	2002);	however,	the	current	study	indicated	
that	the	onset	age	for	childhood‐onset	DRPLA	was	6.4	±	5.0	years.
Assessment	of	the	clinical	progression	in	the	study	cohort	revealed	
that	SCAs	were	the	most	common	etiology	among	patients	with	a	pro‐
gressive	course,	whereas	Joubert	syndrome	and	related	disorders	was	
the most common cause among the nonprogressive cases. Previous 
studies	implicated	that	ataxias	with	congenital	or	nonspecific	causes,	in‐
cluding	cerebral	palsy,	tended	to	exhibit	a	static	course;	an	acute	progres‐
sive	course	might	result	from	intoxications,	infections,	or	inflammatory	
processes; and chronic progressive ataxia might result from genetic dis‐
orders	(Fogel,	2012;	Singer	et	al.,	2015).	These	findings	are	in	agreement	
with	the	current	study	findings,	suggesting	that	genetic	disorders	should	
be considered in chronic progressive cases and that congenital mal‐
formations should be included in the differential diagnosis for nonpro‐
gressive	cases	in	patients	with	childhood‐onset	CA	in	Japan.	However,	
it should be noted that certain genetic disorders with extremely slow 
progression	might	be	misdiagnosed	as	nonprogressive	CA.
Among	the	SCAs	with	a	positive	family	history,	DRPLA	was	the	
most	common	cause;	however,	there	were	four	patients	with	DRPLA	
who had no family history even though a positive family history is a 
common	feature	of	AD	SCAs.	In	the	current	study,	SCA29	(n	=	4)	was	
the	 second	most	 common	 cause	of	AD	SCAs,	with	 three	patients	
exhibiting no family history.
In	the	current	study,	the	mean	onset	age	of	2.3	±	3.5	years	and	
positive	family	history	rate	of	18.8%	within	the	undiagnosed	group	
were	similar	to	those	reported	in	cohorts	from	Canada,	demonstrat‐
ing	that	the	majority	(82%)	of	undiagnosed	cases	presented	at	ages	
younger	than	2	years	and	comprised	a	smaller	population	(19%)	with	
a	positive	family	history	(Al‐Maawali	et	al.,	2012).
TA B L E  3   Multiple logistic regression analysis on clinical features of 252 diagnosed and undiagnosed cases collected via secondary survey
Variables Diagnosed Undiagnosed Odds ratio Lower CL Upper CL p Value
Number of patients 119 133     
Sex	[female:male] 60:59 67:66     
Age	at	onset	[mean	(SD)] 3.4	(4.2) 2.3	(3.5) 1.09 1.01 1.18 .03
Positive	family	history	[N	(%)] 35	(29.4) 25	(18.8) 1.92 1.00 3.69 .05
Motor	developmental	delay	[N	(%)] 66	(55.5) 67	(50.4) 1.67 0.92 3.01 .09
Hearing	issues	[N	(%)] 2	(1.7) 5	(3.8) 0.07 0.01 0.88 .04
Short	stature	[N	(%)] 8	(6.7) 22	(16.5) 0.32 0.12 0.82 .02
Decreased	deep	tendon	reflex	[N	(%)] 21	(17.6) 8	(6.0) 6.38 2.03 20.10 <.01
Note: Odds ratios for other than “age at onset” are described as “yes/no”.
Sex was not selected with the stepwise procedure in the logistic model.
Abbreviations:	CL,	confidence	limit;	SD,	standard	deviation.
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Multiple regression analysis using clinical features as variables indi‐
cated	that	younger	age	of	onset,	hearing	issues,	and	short	stature	were	
risk factors for not receiving a definitive diagnosis for childhood‐onset 
CA	in	Japan.	Patients	with	C10ORF2	mutation,	pontocerebellar	hypo‐
plasia	type	7,	Marinesco–Sjögren	syndrome,	DRPLA,	MECP2	mutation,	
or mitochondrial disorders were included in the diagnosed individu‐
als	who	had	young	age	onset,	with	either	hearing	issue	or	short	stat‐
ure.	Therefore,	these	disorders	may	be	first	considered	as	differential	
diagnosis	 if	not	have	been	assessed.	Further,	AR	SCAs	are	generally	
associated	with	clinical	findings	outside	the	nervous	system	(Fogel	&	
Perlman,	2007;	Singer	et	al.,	2015).	Hearing	issues	and	a	short	stature	
might	be	unrelated	to	the	nervous	system,	and	the	undiagnosed	co‐
hort	of	the	current	study	might	have	included	patients	with	AR	SCAs.	
Another	 speculation	might	 be	 that	 individuals	with	 childhood‐onset	
CA	harboring	hearing	issues	or	a	short	stature	might	be	representing	a	
new disease entity with these signs that is yet to be identified.
In	AD	SCAs,	genetic	panel	testing	screening	is	a	mainstream	di‐
agnostic	approach	for	SCA	types	1,	2,	3,	6,	7,	and	17,	and	DRPLA	(van	
de	Warrenburg	 et	 al.,	 2014).	 Several	 recent	 studies	 demonstrated	
the	utility	of	WES	 for	 the	diagnosis	of	 childhood‐onset	CA,	 espe‐
cially	AR	SCAs,	a	rapidly	expanding	group	following	the	implemen‐
tation	of	this	technology	(Fogel,	2012;	Ohba	et	al.,	2013;	Sasaki	et	
al.,	2015;	Sawyer	et	al.,	2014;	van	de	Warrenburg	et	al.,	2014).	Given	
the	possibility	 that	 there	might	be	patients	with	AR	ataxias	 in	 the	
undiagnosed	group,	the	diagnostic	rate	might	improve	with	the	im‐
plementation of WES for all patients with no definitive diagnosis.
One notable limitation of the current study was the administra‐
tion of the survey to a limited number of physicians and facilities. 
Nonetheless,	to	best	of	our	knowledge,	this	is	the	first	study	to	in‐
vestigate	patients	with	childhood‐onset	CA	in	Japan,	providing	new	
insights on the prevalence and etiologies and the feasibility of po‐
tential predictors of diagnosis in these patients.
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APPENDIX 1
TA B L E  A 1   Summary of the 119 diagnosed cases collected via secondary survey
Diagnosis Number of patients Disease category
Dentatorubropallidoluysian atrophy 20 SCAs
Mitochondrial disorder 14 Inborn error of metabolism
Joubert syndrome and related disorder 12 Joubert syndrome and related disorder
Ataxia	telangiectasia	and	related	disorders 11 SCAs
Encephalitis 6 Encephalitis
Ataxia	with	oculomotor	apraxia	type	1 5 SCAs
SCA29 4 SCAs
CASK mutation 4 Other genetic disorders
CACNA1A mutation 4 Other genetic disorders
Glut1	deficiency 3 Inborn error of metabolism
KIF1A mutation 3 Other genetic disorders
Dandy–Walker	variants 2 Brain malformation
SEPSECS mutation 2 Pontocerebellar hypoplasia
Congenital disorder of glycosylation 2 Inborn error of metabolism
Marinesco–Sjögren	syndrome 2 SCAs
Peroxisomal biogenesis disorders 2 Inborn error of metabolism
PLA2G6‐associated neurodegeneration 2 Other genetic disorders
TUBA1A mutation 1 Brain malformation
Cerebellar hypoplasia 1 Brain malformation
Holoprosencephaly 1 Brain malformation
Pontocerebellar hypoplasia type 7 1 Pontocerebellar hypoplasia
Chromosome 22 partial duplication 1 Chromosomal and congenital abnormality
Cockayne syndrome 1 Chromosomal and congenital abnormality
Phelan–McDermid	syndrome 1 Chromosomal and congenital abnormality
Phenytoin side effect 1 Others
Opsoclonus myoclonus syndrome 1 Paraneoplastic cerebellar degeneration
SCA5 1 SCAs
SCA13 1 SCAs
SCA2 1 SCAs
Infantile‐onset spinocerebellar degeneration 1 SCAs
Friedreich	ataxiaa 1 SCAs
Spinocerebellar degeneration 1 SCAs
Multiple system atrophy 1 SCAs
KCNA2 mutation 1 Other genetic disorders
LONP1 mutation 1 Other genetic disorders
MECP2 duplication 1 Other genetic disorders
STXBP1 mutation 1 Other genetic disorders
Chédiak‐Higashi syndrome 1 Abnormal	immune	system
Abbreviation:	SCA,	spinocerebellar	ataxia.
aNot confirmed by gene analysis. 
